Jeffrey M. Rybak

2.8k total citations · 1 hit paper
38 papers, 2.0k citations indexed

About

Jeffrey M. Rybak is a scholar working on Infectious Diseases, Epidemiology and Pharmacology. According to data from OpenAlex, Jeffrey M. Rybak has authored 38 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Infectious Diseases, 20 papers in Epidemiology and 9 papers in Pharmacology. Recurrent topics in Jeffrey M. Rybak's work include Antifungal resistance and susceptibility (26 papers), Fungal Infections and Studies (17 papers) and Pneumocystis jirovecii pneumonia detection and treatment (7 papers). Jeffrey M. Rybak is often cited by papers focused on Antifungal resistance and susceptibility (26 papers), Fungal Infections and Studies (17 papers) and Pneumocystis jirovecii pneumonia detection and treatment (7 papers). Jeffrey M. Rybak collaborates with scholars based in United States, United Kingdom and Germany. Jeffrey M. Rybak's co-authors include P. David Rogers, Katherine S. Barker, Andrew T. Nishimoto, Elizabeth L. Berkow, Sarah Whaley, Michael J. Rybak, Evan J Zasowski, Jarrod R. Fortwendel, Christina A. Cuomo and Glen E. Palmer and has published in prestigious journals such as Nature Communications, Scientific Reports and The Journal of Infectious Diseases.

In The Last Decade

Jeffrey M. Rybak

32 papers receiving 2.0k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species

2017 657 citations Sarah Whaley, Elizabeth L. Berkow et al. Frontiers in Microbiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey M. Rybak United States	21	1.4k	929	405	348	292	38	2.0k
Daniel J. Sheehan United States	17	1.6k 1.2×	1.0k 1.1×	302 0.7×	386 1.1×	149 0.5×	35	2.6k
Gary J. Moet United States	19	1.7k 1.2×	1.1k 1.2×	232 0.6×	276 0.8×	314 1.1×	24	2.3k
Samuel A. Lee United States	25	1.3k 0.9×	918 1.0×	148 0.4×	738 2.1×	163 0.6×	50	2.2k
László Majoros Hungary	22	988 0.7×	667 0.7×	216 0.5×	371 1.1×	84 0.3×	97	1.4k
Erja Chryssanthou Sweden	30	1.7k 1.3×	1.6k 1.8×	275 0.7×	316 0.9×	151 0.5×	71	2.8k
Ken Bartizal United States	27	1.9k 1.4×	1.3k 1.3×	535 1.3×	425 1.2×	125 0.4×	49	2.6k
Karen Marchillo United States	34	2.7k 2.0×	1.6k 1.7×	922 2.3×	821 2.4×	276 0.9×	52	3.4k
Barbara Zimmer United States	21	784 0.6×	952 1.0×	146 0.4×	429 1.2×	322 1.1×	41	2.0k
Shaoji Cheng United States	24	967 0.7×	934 1.0×	763 1.9×	411 1.2×	949 3.3×	47	2.1k
Gloria M. González Mexico	31	2.2k 1.6×	2.0k 2.1×	229 0.6×	368 1.1×	156 0.5×	163	3.1k

Countries citing papers authored by Jeffrey M. Rybak

Since Specialization

Citations

This map shows the geographic impact of Jeffrey M. Rybak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey M. Rybak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey M. Rybak more than expected).

Fields of papers citing papers by Jeffrey M. Rybak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey M. Rybak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey M. Rybak. The network helps show where Jeffrey M. Rybak may publish in the future.

Co-authorship network of co-authors of Jeffrey M. Rybak

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey M. Rybak. A scholar is included among the top collaborators of Jeffrey M. Rybak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey M. Rybak. Jeffrey M. Rybak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Velde, Sam Van de, Hans Carolus, Paul Vandecruys, et al.. (2025). Accumulation of Trehalose 6-Phosphate in Candidozyma auris results in Decreased Echinocandin Resistance and Tolerance. Nature Communications. 17(1). 311–311.

Rybak, Jeffrey M., et al.. (2025). A Candidozyma ( Candida ) auris– Optimized Episomal Plasmid–Induced Cas9-Editing System Reveals the Direct Impact of the S639F-Encoding FKS1 Mutation. The Journal of Infectious Diseases. 232(3). e529–e536. 3 indexed citations

Jones, Sarah, I. M. Richardson, Philip Dykema, et al.. (2025). Acquired amphotericin B resistance attributed to a mutated ERG3 in Candidozyma auris. Antimicrobial Agents and Chemotherapy. 69(11). e0060125–e0060125.

Barker, Katherine S., Qing Zhang, Tracy L. Peters, et al.. (2025). Relative contributions of the ERG11VF125AL and MRR1AN647T mutations to fluconazole resistance in Clade III Candidozyma (Candida) auris clinical isolates. Clinical Microbiology and Infection. 32(2). 285–291.

Lou, Jinchao, Jeffrey M. Rybak, Peter Oelkers, et al.. (2024). The small molecule CBR-5884 inhibits the Candida albicans phosphatidylserine synthase. mBio. 15(5). e0063324–e0063324. 5 indexed citations

Rybak, Jeffrey M., Jinhong Xie, Adela Martín‐Vicente, et al.. (2024). A secondary mechanism of action for triazole antifungals in Aspergillus fumigatus mediated by hmg1. Nature Communications. 15(1). 3642–3642. 22 indexed citations

Rybak, Jeffrey M., et al.. (2024). Analysis of clinical Candida parapsilosis isolates reveals copy number variation in key fluconazole resistance genes. Antimicrobial Agents and Chemotherapy. 68(6). e0161923–e0161923. 5 indexed citations

Carolus, Hans, Poppy Sephton-Clark, Rudy Vergauwen, et al.. (2024). Acquired amphotericin B resistance leads to fitness trade-offs that can be mitigated by compensatory evolution in Candida auris. Nature Microbiology. 9(12). 3304–3320. 21 indexed citations

Souza, Ana Camila Oliveira, Wenbo Ge, Nathan P. Wiederhold, et al.. (2023). hapE and hmg1 Mutations Are Drivers of cyp51A -Independent Pan-Triazole Resistance in an Aspergillus fumigatus Clinical Isolate. Microbiology Spectrum. 11(3). e0518822–e0518822. 8 indexed citations

10.

Barker, Katherine S., et al.. (2023). Mutations in TAC1 and ERG11 are major drivers of triazole antifungal resistance in clinical isolates of Candida parapsilosis. Clinical Microbiology and Infection. 29(12). 1602.e1–1602.e7. 13 indexed citations

11.

Rybak, Jeffrey M., Christina A. Cuomo, & P. David Rogers. (2022). The molecular and genetic basis of antifungal resistance in the emerging fungal pathogen Candida auris. Current Opinion in Microbiology. 70. 102208–102208. 60 indexed citations

12.

Rybak, Jeffrey M., et al.. (2022). Candida parapsilosis Mdr1B and Cdr1B Are Drivers of Mrr1-Mediated Clinical Fluconazole Resistance. Antimicrobial Agents and Chemotherapy. 66(7). e0028922–e0028922. 21 indexed citations

13.

Rybak, Jeffrey M., Katherine S. Barker, José F. Muñoz, et al.. (2021). In vivo emergence of high-level resistance during treatment reveals the first identified mechanism of amphotericin B resistance in Candida auris. Clinical Microbiology and Infection. 28(6). 838–843. 77 indexed citations

14.

Smith, Jordan R., Jeffrey M. Rybak, & Kimberly C. Claeys. (2020). Imipenem‐Cilastatin‐Relebactam: A Novel β‐Lactam–β‐Lactamase Inhibitor Combination for the Treatment of Multidrug‐Resistant Gram‐Negative Infections. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 40(4). 343–356. 60 indexed citations

15.

Rybak, Jeffrey M., José F. Muñoz, Katherine S. Barker, et al.. (2020). Mutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris. mBio. 11(3). 135 indexed citations

16.

Rybak, Jeffrey M., Wenbo Ge, Nathan P. Wiederhold, et al.. (2019). Mutations in hmg1 , Challenging the Paradigm of Clinical Triazole Resistance in Aspergillus fumigatus. mBio. 10(2). 82 indexed citations

17.

Whaley, Sarah, Elizabeth L. Berkow, Jeffrey M. Rybak, et al.. (2017). Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species. Frontiers in Microbiology. 7. 2173–2173. 657 indexed citations breakdown →

18.

Rybak, Jeffrey M., et al.. (2016). Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections. Infectious Diseases and Therapy. 5(1). 1–15. 80 indexed citations

19.

Rybak, Jeffrey M., et al.. (2015). Tedizolid Phosphate: a Next-Generation Oxazolidinone. Infectious Diseases and Therapy. 4(1). 1–14. 60 indexed citations

20.

Rybak, Jeffrey M., Katie E. Barber, & Michael J. Rybak. (2013). Current and prospective treatments for multidrug-resistant gram-positive infections. Expert Opinion on Pharmacotherapy. 14(14). 1919–1932. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact